KISS1R (D9D7C) Rabbit mAb #13776
- WB
- IP
Supporting Data
| REACTIVITY | H |
| SENSITIVITY | Endogenous |
| MW (kDa) | 40-140 |
| Source/Isotype | Rabbit IgG |
Application Key:
- WB-Western Blotting
- IP-Immunoprecipitation
Species Cross-Reactivity Key:
- H-Human
Product Information
Product Usage Information
| Application | Dilution |
|---|---|
| Western Blotting | 1:1000 |
| Immunoprecipitation | 1:50 |
Storage
Protocol
Specificity / Sensitivity
KISS1R (D9D7C) Rabbit mAb recognizes endogenous levels of total KISS1R protein.
Species Reactivity:
Human
Source / Purification
Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues near the carboxy terminus of human KISS1R protein.
Background
The KiSS-1 receptor (KISS1R, GPR54) is a G protein-coupled receptor that inhibits cancer cell metastasis and plays a major role in gonadotropic axis physiology (1). The GPR54 protein was originally described as an orphan receptor homologous to the galanin receptor, and later identified as a receptor for amidated peptide products of the metastasis suppressor gene KiSS-1 (KISS1, Kisspeptin-1) (2,3). In humans, amidated kisspeptin ligands are produced predominantly in cells of the arcuate nucleus and preoptic area, with expression controlled by gonadal hormones (4). Research studies show that deletion of either the KiSS-1 receptor or KiSS-1 gene leads to hypogonadotropic hypogonadism, a disorder characterized by reduced levels of circulating testosterone and gonadotropins, as well as abnormal sexual maturation (5,6). The administration of kisspeptins potently stimulates gonadotropin secretion, indicating that KISS1R and kisspeptins play a major role in the physiology of the gonadotropic axis (7). Additional research demonstrates that KISS1R and kisspeptins inhibit metastasis in cancer cells by inhibiting cell motility (8). However, other studies indicate that increased expression of KISS1R and its ligands in human breast tumors correlates with higher tumor grade and metastatic potential, likely by engaging MMP-9 activation via transactivation of EGFR (9).
- Beck, B.H. and Welch, D.R. (2010) Eur J Cancer 46, 1283-9.
- Lee, D.K. et al. (1999) FEBS Lett 446, 103-7.
- Ohtaki, T. et al. (2001) Nature 411, 613-7.
- Lehman, M.N. et al. (2010) Brain Res 1364, 90-102.
- de Roux, N. et al. (2003) Proc Natl Acad Sci U S A 100, 10972-6.
- d'Anglemont de Tassigny, X. et al. (2007) Proc Natl Acad Sci U S A 104, 10714-9.
- Gottsch, M.L. et al. (2004) Endocrinology 145, 4073-7.
- Cho, S.G. et al. (2012) Cancer Metastasis Rev 31, 585-91.
- Zajac, M. et al. (2011) PLoS One 6, e21599.
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.